Annual CFF
$17.82 M
-$292.85 M-94.26%
December 31, 2023
Summary
- As of February 26, 2025, DNLI annual cash flow from financing activities is $17.82 million, with the most recent change of -$292.85 million (-94.26%) on December 31, 2023.
- During the last 3 years, DNLI annual CFF has fallen by -$616.93 million (-97.19%).
- DNLI annual CFF is now -97.19% below its all-time high of $634.75 million, reached on December 31, 2020.
Performance
DNLI Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
-$18.56 M
-$25.32 M-374.70%
September 30, 2024
Summary
- As of February 26, 2025, DNLI quarterly cash flow from financing activities is -$18.56 million, with the most recent change of -$25.32 million (-374.70%) on September 30, 2024.
- Over the past year, DNLI quarterly CFF has stayed the same.
- DNLI quarterly CFF is now -103.71% below its all-time high of $500.27 million, reached on March 31, 2024.
Performance
DNLI Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$493.18 M
-$21.05 M-4.09%
September 30, 2024
Summary
- As of February 26, 2025, DNLI TTM cash flow from financing activities is $493.18 million, with the most recent change of -$21.05 million (-4.09%) on September 30, 2024.
- Over the past year, DNLI TTM CFF has stayed the same.
- DNLI TTM CFF is now -22.30% below its all-time high of $634.75 million, reached on December 31, 2020.
Performance
DNLI TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
DNLI Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -94.3% | 0.0% | 0.0% |
| 3 y3 years | -97.2% | -106.2% | +58.8% |
| 5 y5 years | -81.6% | -106.2% | +58.8% |
DNLI Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -94.3% | at low | -103.7% | at low | -4.5% | +3337.3% |
| 5 y | 5-year | -97.2% | +187.9% | -103.7% | at low | -22.3% | +7867.3% |
| alltime | all time | -97.2% | +187.9% | -103.7% | at low | -22.3% | >+9999.0% |
Denali Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$18.56 M(-374.7%) | $493.18 M(-4.1%) |
| Jun 2024 | - | $6.76 M(-98.6%) | $514.23 M(-0.4%) |
| Mar 2024 | - | $500.27 M(>+9900.0%) | $516.49 M(+2798.4%) |
| Dec 2023 | $17.82 M(-94.3%) | $4.71 M(+88.8%) | $17.82 M(-94.3%) |
| Sep 2023 | - | $2.49 M(-72.4%) | $312.77 M(-0.8%) |
| Jun 2023 | - | $9.02 M(+462.3%) | $315.43 M(+1.5%) |
| Mar 2023 | - | $1.60 M(-99.5%) | $310.81 M(+0.0%) |
| Dec 2022 | $310.67 M(+1505.7%) | $299.65 M(+5714.0%) | $310.67 M(+1819.3%) |
| Sep 2022 | - | $5.15 M(+17.1%) | $16.19 M(+12.8%) |
| Jun 2022 | - | $4.40 M(+200.9%) | $14.35 M(-15.5%) |
| Mar 2022 | - | $1.46 M(-71.7%) | $16.99 M(-12.2%) |
| Dec 2021 | $19.35 M(-97.0%) | $5.17 M(+55.9%) | $19.35 M(-18.4%) |
| Sep 2021 | - | $3.31 M(-52.9%) | $23.70 M(-94.7%) |
| Jun 2021 | - | $7.04 M(+84.3%) | $446.29 M(+0.8%) |
| Mar 2021 | - | $3.82 M(-59.9%) | $442.66 M(-30.3%) |
| Dec 2020 | $634.75 M | $9.52 M(-97.8%) | $634.75 M(+1.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | $425.90 M(>+9900.0%) | $627.26 M(+210.5%) |
| Jun 2020 | - | $3.42 M(-98.3%) | $202.04 M(+0.4%) |
| Mar 2020 | - | $195.91 M(+9531.9%) | $201.19 M(+3150.3%) |
| Dec 2019 | $6.19 M(-93.6%) | $2.03 M(+199.6%) | $6.19 M(+5.9%) |
| Sep 2019 | - | $679.00 K(-73.6%) | $5.85 M(+0.4%) |
| Jun 2019 | - | $2.57 M(+182.9%) | $5.83 M(+24.3%) |
| Mar 2019 | - | $908.00 K(-46.3%) | $4.69 M(-95.2%) |
| Dec 2018 | $97.02 M(-67.3%) | $1.69 M(+156.8%) | $97.02 M(-75.2%) |
| Sep 2018 | - | $658.00 K(-54.1%) | $390.92 M(+0.1%) |
| Jun 2018 | - | $1.43 M(-98.5%) | $390.62 M(+0.4%) |
| Mar 2018 | - | $93.24 M(-68.5%) | $389.24 M(+31.4%) |
| Dec 2017 | $296.32 M(-1.4%) | $295.59 M(>+9900.0%) | $296.32 M(>+9900.0%) |
| Sep 2017 | - | $357.00 K(+600.0%) | $732.00 K(+95.2%) |
| Jun 2017 | - | $51.00 K(-84.3%) | $375.00 K(+15.7%) |
| Mar 2017 | - | $324.00 K | $324.00 K |
| Dec 2016 | $300.48 M(+515.0%) | - | - |
| Dec 2015 | $48.85 M | - | - |
FAQ
- What is Denali Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Denali Therapeutics?
- What is Denali Therapeutics annual CFF year-on-year change?
- What is Denali Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Denali Therapeutics?
- What is Denali Therapeutics quarterly CFF year-on-year change?
- What is Denali Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Denali Therapeutics?
- What is Denali Therapeutics TTM CFF year-on-year change?
What is Denali Therapeutics annual cash flow from financing activities?
The current annual CFF of DNLI is $17.82 M
What is the all time high annual CFF for Denali Therapeutics?
Denali Therapeutics all-time high annual cash flow from financing activities is $634.75 M
What is Denali Therapeutics annual CFF year-on-year change?
Over the past year, DNLI annual cash flow from financing activities has changed by -$292.85 M (-94.26%)
What is Denali Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of DNLI is -$18.56 M
What is the all time high quarterly CFF for Denali Therapeutics?
Denali Therapeutics all-time high quarterly cash flow from financing activities is $500.27 M
What is Denali Therapeutics quarterly CFF year-on-year change?
Over the past year, DNLI quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is Denali Therapeutics TTM cash flow from financing activities?
The current TTM CFF of DNLI is $493.18 M
What is the all time high TTM CFF for Denali Therapeutics?
Denali Therapeutics all-time high TTM cash flow from financing activities is $634.75 M
What is Denali Therapeutics TTM CFF year-on-year change?
Over the past year, DNLI TTM cash flow from financing activities has changed by $0.00 (0.00%)